---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-110696"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:52:17.452528+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma and ALK co-promote neffy nasal spray to up to 9,000 U.S. pediatricians

## Summary
- Co-promotion agreement with ALK-Abelló, Inc. for neffy (epinephrine nasal spray) targeting pediatricians and other prescribers.
- ALK starts promotion activities May 2025, must meet ramp-up milestones and minimum detail requirements; non-compete on injectable epinephrine.
- ARS books all U.S. sales; ALK receives base fee (first-year deferred) and performance bonuses from year 2: 30% of net sales above preset market share thresholds.
- Agreement expires after 4 years; termination provisions include for convenience (with fee) and change of control (mid-seven to low eight-digit fee).

## SEC filing metadata
- accession: 0001193125-25-110696
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312525110696/0001193125-25-110696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312525110696/d26679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-110696
- JSON: https://secwatch.observer/filing/0001193125-25-110696.json
- Plain text: https://secwatch.observer/filing/0001193125-25-110696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.